Psilocybin, a psychedelic compound, shows promise in treating major depressive disorder by rewiring neural circuitry. It primarily interacts with serotonin receptors, particularly the 5H2A receptor, leading to diverse effects on brain function. Clinical studies led by researchers like Matthew are exploring its therapeutic potential, aiming to provide evidence-based insights into its efficacy for alleviating depression.